Visionary CMO with 20+ years of board experience and executive leadership (VP,then Chief Medical Officer) in biopharmaceutical companies and foundations.

• My strengths include leading global drug and vaccine development to

approval and commercialization; aligning board members, executive teams

and operational teams around a shared vision; excelling at communicating

with investors and building solid partnerships with stakeholders; having

large domestic and international networks; proven problem-solving abilities

(pipeline analysis, business development deals, partnership agreements).

• My expertise is creating value through cross-sector collaborations

(biopharma, non-profit, and patient advocacy organizations).

• My track record includes driving the FDA approval and supporting the

market launch of two novel drugs, generating revenue growth; leading the

anti-malarial interventions’ portfolio transformation at the Bill and Melinda

Gates Foundation; and spearheading a complex adaptive Phase 2/3 trial in

pancreatic cancer at PanCAN.

I am seeking board positions with organizations that drive transformative healthcare innovations, require strategic guidance for complex drug development efforts/market expansion, and preferably demonstrate a commitment to expanding medical access in low and middle-income countries.

As a Board Member:

• Board of Fe Pharmaceuticals (2020-present): Chair as of 2023; member,

Compensation Committee; and Co-chair, Scientific Advisory Board; leading

advisor for the clinical and regulatory strategies (serious infections/sepsis);

play a key role in networking for seed and Series A fundraising with

institutional investors, high net-worth individuals, and foundations.

• Board of the California Institute of Regenerative Medicine (2012-present):

help guide the spending of $8.5 billion to accelerate stem cell research;

member, Application Review, Finance, Governance, and IP/Industry

committees.

• Board of the AIDS Vaccine Advocacy Coalition (2005-2023); reviewed the

organizational mission and the strategic planning; guided the organizational

evaluation; member, DEI committee.

As a Member of Executive Teams

• Extensive product development experience (30+ years): adept at

navigating complex regulatory environments; depth and breadth across

hematology, immunology, nephrology, infectious diseases (including HIV

and malaria) & rare/orphan diseases.

• BMGF Deputy Director: led the antimalaria interventions and diagnostics

efforts toward eradicating malaria worldwide.

• PanCAN CMO: provided the strategic direction and operational oversight

for the clinical sciences and medical affairs departments.

• Rigel Pharmaceuticals CMO: brought the company’s flagship product to

market; contributed to doubling the company’s valuation in 18 months;

supported the CEO in raising $165 million in 3 rounds.

• Affymax CMO: brought the company’s flagship product to market;

successful IPO in 2006; $500+ million partnership with Takeda.